Clinical trial · Interventional
Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer
A Phase II Study Of Alternating Chemoradiotherapy For Nasopharyngeal Cancer Using Cisplatin And 5-Fluorouracil
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining fluorouracil and cisplatin with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving fluorouracil and cisplatin together with radiation therapy works in treating patients with stage II, stage III, or stage IV nasopharyngeal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| fluorouracil | Drug | Fluorouracil | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival at 3 years
Secondary outcomes (4)
- measure
- Overall survival
- measure
- Response rate
- measure
- Treatment completion rate
- measure
- Incidence of adverse effects
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed nasopharyngeal cancer (NPC)
* Type I-III disease by WHO classification
* Stage IIB-IVB disease by TNM classification with no distant metastases by chest x-ray, liver ultrasonography or CT scan, and bone scintigraphy
* Lymph node metastases evaluated by CT scan, MRI, and palpation
* Progression range of primary lesion evaluated by MRI and pharyngeal fiberoptic endoscopy
PATIENT CHARACTERISTICS:
Age
* 18 to 70
Performance status
* ECOG 0-2
Life expectancy
* Not specified
Hematopoietic
* WBC \> 3,500/mm\^3
* Platelet count \> 100,000/mm\^3
Hepatic
* No severe hepatic dysfunction
Renal
* Creatinine clearance \> 60 mL/min
* No severe renal dysfunction
Cardiovascular
* No severe cardiac dysfunction
Pulmonary
* No severe pulmonary dysfunction
Other
* No other active cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy
* No prior biologic therapy for NPC
Chemotherapy
* No prior systemic chemotherapy for NPC
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* Not specifiedReferences
Publications (0)
Data not yet available